君实生物 · Junshi Biosciences
← News archive

· Clinical research

Phase 3 lymphoma trial of JS203 and chemotherapy doses first patient

Junshi reported first patient dosing in a Phase 3 study of JS203 plus chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.

The study compares the investigational regimen with rituximab plus chemotherapy. The trial is registered as NCT07808827.

Read the full company release